Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah E Davis

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
The Journal of Pharmacology and Experimental Therapeutics|September 16, 2024
<b>Identification of pyrimidine structure-based compounds as allosteric ligands of the dopamine transporter as therapeutic agents for NeuroHIV</b>Ana Catya Jimenez-Torres, Jamison A Hastie, Sarah E Davis, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2025
Identification of pyrimidine structure-based compounds as allosteric ligands of the dopamine transporter as therapeutic agents for NeuroHIVAna Catya Jimenez-Torres, Jamison A Hastie, Sarah E Davis, et al.
Infection and Immunity|June 6, 2018
Candida albicans Cannot Acquire Sufficient Ethanolamine from the Host To Support Virulence in the Absence of <i>De Novo</i> Phosphatidylethanolamine SynthesisSarah E Davis, Robert N Tams, Norma V Solis, et al.
Breast Cancer Research : BCR|May 30, 2015
Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and responseMark Jesus M Magbanua, Denise M Wolf, Christina Yau, et al.
Mbio|December 20, 2018
Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal VirulenceYoon-Dong Park, Joseph N Jarvis, Guowu Hu, et al.
The Journal of Experimental Medicine|March 21, 2012
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibitionDai Horiuchi, Leonard Kusdra, Noelle E Huskey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657Laura J Esserman, Donald A Berry, Angela DeMichele, et al.
Breast Cancer Research and Treatment|December 27, 2011
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Laura J Esserman, Donald A Berry, Maggie C U Cheang, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Neratinib in Early Breast CancerJohn W Park, Minetta C Liu, Douglas Yee, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast CancerHope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
The Journal of Pharmacology and Experimental Therapeutics|September 16, 2024
<b>Identification of pyrimidine structure-based compounds as allosteric ligands of the dopamine transporter as therapeutic agents for NeuroHIV</b>Ana Catya Jimenez-Torres, Jamison A Hastie, Sarah E Davis, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2025
Identification of pyrimidine structure-based compounds as allosteric ligands of the dopamine transporter as therapeutic agents for NeuroHIVAna Catya Jimenez-Torres, Jamison A Hastie, Sarah E Davis, et al.
Infection and Immunity|June 6, 2018
Candida albicans Cannot Acquire Sufficient Ethanolamine from the Host To Support Virulence in the Absence of <i>De Novo</i> Phosphatidylethanolamine SynthesisSarah E Davis, Robert N Tams, Norma V Solis, et al.
Breast Cancer Research : BCR|May 30, 2015
Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and responseMark Jesus M Magbanua, Denise M Wolf, Christina Yau, et al.
Mbio|December 20, 2018
Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal VirulenceYoon-Dong Park, Joseph N Jarvis, Guowu Hu, et al.
The Journal of Experimental Medicine|March 21, 2012
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibitionDai Horiuchi, Leonard Kusdra, Noelle E Huskey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657Laura J Esserman, Donald A Berry, Angela DeMichele, et al.
Breast Cancer Research and Treatment|December 27, 2011
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Laura J Esserman, Donald A Berry, Maggie C U Cheang, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Neratinib in Early Breast CancerJohn W Park, Minetta C Liu, Douglas Yee, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast CancerHope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, et al.
Pageof 4